The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27

被引:29
|
作者
Rosner, Margit [1 ]
Freilinger, Angelika [1 ]
Hengstschaeger, Markus [1 ]
机构
[1] Med Univ Vienna, A-1090 Vienna, Austria
关键词
p27; TSC1; TSC2; tuberous sclerosis; tumor suppressor;
D O I
10.1016/j.mrrev.2006.03.001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Tuberous sclerosis complex (TSC) is an autosomal dominant tumor syndrome that affects similar to 1 in 6000 individuals. It is characterized by the development of tumors, named hamartomas, in the kidneys, heart, skin and brain. The latter often cause seizures, mental retardation, and a variety of developmental disorders, including autism. This disease is caused by mutations within the tumor suppressor gene TSCI on chromosome 9q34 encoding hamartin or within TSC2 on chromosome 16p13.3 encoding tuberin. TSC patients carry a mutant TSC1 or TSC2 gene in each of their somatic cells, and loss of heterozygosity has been documented in a wide variety of TSC tumors. Recent data suggest that functional inactivation of TSC proteins might also be involved in the development of other diseases not associated with TSC, such as sporadic bladder cancer, breast cancer, ovarian carcinoma, gall bladder carcinoma, non-small-cell carcinoma of the lung, and Alzheimer's disease. Tuberin and hamartin form a heterodimer, suggesting they might affect the same processes. Tuberin is assumed to be the functional component of the complex and has been implicated in the regulation of different cellular functions. The TSC proteins regulate cell size control due to their involvement in the insulin signalling pathway. Furthermore, they are potent positive regulators of the cyclin-dependent kinase inhibitor p27, a major regulator of the mammalian cell cycle. Here we review the current knowledge on how mutations within the TSC genes could trigger deregulation of stability and localization of the tumor suppressor p27. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:10 / 16
页数:7
相关论文
共 50 条
  • [31] Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas
    Shigemasa, K
    Shiroyama, Y
    Sawasaki, T
    Fujii, T
    Nagai, N
    Parmley, TH
    O'Brien, TJ
    Ohama, K
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 18 (05) : 953 - 958
  • [32] SGK1-Sensitive Regulation of Cyclin-Dependent Kinase Inhibitor 1B (p27) in Cardiomyocyte Hypertrophy
    Voelkl, Jakob
    Castor, Tatsiana
    Musculus, Katharina
    Viereck, Robert
    Mia, Sobuj
    Feger, Martina
    Alesutan, Ioana
    Lang, Florian
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2015, 37 (02) : 603 - 614
  • [33] Upregulation of cyclin-dependent kinase inhibitor p27 by salicylates inhibits vascular smooth muscle proliferation
    Marra, DE
    Liao, JK
    [J]. CIRCULATION, 1998, 98 (17) : 599 - 600
  • [34] Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas
    Qi, CF
    Xiang, S
    Shin, MS
    Hao, XP
    Lee, CH
    Zhou, JX
    Torrey, TA
    Hartley, JW
    Fredrickson, TN
    Morse, HC
    [J]. LEUKEMIA RESEARCH, 2006, 30 (02) : 153 - 163
  • [35] Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation
    Durand, B
    Gao, FB
    Raff, M
    [J]. EMBO JOURNAL, 1997, 16 (02): : 306 - 317
  • [36] ROLE OF THE UBIQUITIN-PROTEASOME PATHWAY IN REGULATING ABUNDANCE OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P27
    PAGANO, M
    TAM, SW
    THEODORAS, AM
    BEERROMERO, P
    DELSAL, G
    CHAU, V
    YEW, PR
    DRAETTA, GF
    ROLFE, M
    [J]. SCIENCE, 1995, 269 (5224) : 682 - 685
  • [38] Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Cdk2
    Morisaki, H
    Fujimoto, A
    Ando, A
    Nagata, Y
    Ikeda, K
    Nakanishi, M
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 240 (02) : 386 - 390
  • [39] Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers
    Hur, Saem
    Kim, Ju Hee
    Yun, Jihui
    Ju, Young Wook
    Han, Jong Min
    Heo, Woohang
    Kim, Kwangsoo
    Jeong, Kyeonghun
    Lee, Han-Byoel
    Han, Wonshik
    Noh, Dong-Young
    Hong, Dongwan
    Moon, Hyeong-Gon
    [J]. JOURNAL OF BREAST CANCER, 2020, 23 (02) : 162 - 170
  • [40] Expression and significance of cyclin D1, cyclin-dependent kinase 4 and cyclin-dependent kinase inhibitor P27 in patients with non-neoplastic epithelial disorders of the vulva
    Liu, Huamei
    Zhang, Fan
    Li, Zongheng
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (01)